The risks of risk aversion in drug regulation (Q38162718)

30 August 2017

title

The risks of risk aversion in drug regulation (English)

1 reference

30 August 2017

Hans-Georg Eichler

1

1 reference

30 August 2017

Brigitte Bloechl-Daum

2

1 reference

30 August 2017

Daniel Brasseur

3

1 reference

30 August 2017

Alasdair Breckenridge

4

1 reference

30 August 2017

Hubert Leufkens

5

1 reference

30 August 2017

June Raine

6

1 reference

30 August 2017

Tomas Salmonson

7

1 reference

30 August 2017

Christian K Schneider

8

1 reference

30 August 2017

Guido Rasi

9

1 reference

30 August 2017

language of work or name

1 reference

15 November 2013

1 reference

Nature Reviews Drug Discovery

30 August 2017

published in

1 reference

30 August 2017

volume

12

1 reference

30 August 2017

issue

12

1 reference

30 August 2017

page(s)

907-916

1 reference

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

30 August 2017

cites work

1 reference

Primum non nocere? Valuing of the risk of drug toxicity in therapeutic decision making.

21 January 2018

1 reference

On the elicitation of preferences for alternative therapies.

21 January 2018

1 reference

The Age-Old Struggle against the Antivaccinationists

21 January 2018

1 reference

Enhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reaction

21 January 2018

1 reference

The safety risks of innovation: the FDA's Expedited Drug Development Pathway

21 January 2018

1 reference

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

21 January 2018

1 reference

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

21 January 2018

1 reference

Symmetrical analysis of risk–benefit

21 January 2018

1 reference

The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies.

21 January 2018

1 reference

Specific barriers to the conduct of randomized trials.

21 January 2018

1 reference

Impediments to Clinical Research in the United States

21 January 2018

1 reference

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

New medicines for type 2 diabetes in adolescents: many products, few patients

21 January 2018

1 reference

Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy.

21 January 2018

1 reference

Fifty years after thalidomide; what role for drug regulators?

21 January 2018

1 reference

A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group

21 January 2018

1 reference

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

Design of the Women’s Health Initiative Clinical Trial and Observational Study

21 January 2018

1 reference

Dabigatran and postmarketing reports of bleeding

21 January 2018

1 reference

Cutting the cost of drug development?

21 January 2018

1 reference

Mediator scandal rocks French medical community

21 January 2018

1 reference

Relapsing-remitting multiple sclerosis patients' experience with natalizumab: a phenomenological investigation

21 January 2018

1 reference

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

21 January 2018

1 reference

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences

21 January 2018

1 reference

Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm

21 January 2018

1 reference

The cost-effectiveness of periodic safety update reports for biologicals in Europe

21 January 2018

1 reference

Commercializing biomedical research through securitization techniques

31 March 2020

1 reference

Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation

31 March 2020

1 reference

The FDA and safe use of long-acting beta-agonists in the treatment of asthma

31 March 2020

1 reference

Withdrawal of generic budeprion for nonbioequivalence

31 March 2020

1 reference

Is marketing the enemy of pharmaceutical innovation?

31 March 2020

1 reference

Drug-Induced PML: A Global Agenda for a Global Challenge

31 March 2020

1 reference

Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24232377

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24232377

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Trust, emotion, sex, politics, and science: surveying the risk-assessment battlefield

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24232377

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD4129

1 reference

30 August 2017

1 reference